ALB and hereditary elliptocytosis: Although long-term therapy with albumin has showed to significantly reduce the risk of infections and grade III-IV HE improving survival in a randomized controlled trial (RCT) including outpatients with cirrhosis and uncomplicated ascites (30), this beneficial effect was not confirmed in hospitalized patients with more advanced disease treated with a short course of albumin (31).